AmerisourceBergen Reports Fourth Quarter and Fiscal Year 2012 Results

  AmerisourceBergen Reports Fourth Quarter and Fiscal Year 2012 Results

  *Fourth quarter GAAP diluted EPS from continuing operations of $0.65, up
    23%
  *Fiscal year 2012 GAAP diluted EPS from continuing operations of $2.76, up
    10%
  *Non-recurring items had a net negative impact of $0.04 per share in the
    fourth quarter and $0.07 per share for fiscal year 2012
  *Company pursuing sale of AndersonBrecon, classifies earnings generated
    from the business as income from discontinued operations
  *$650 million accelerated share repurchase program completed during the
    fourth quarter
  *Board of Directors increased annual dividend by 62% to $0.84 per share,
    and authorized an additional $750 million in share repurchases
  *FY2013 GAAP diluted EPS from continuing operations expected to be in the
    range of $3.06 to $3.16

Business Wire

VALLEY FORGE, Pa. -- November 01, 2012

AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal
year 2012 fourth quarter ended September 30, 2012, diluted earnings per share
from continuing operations increased 23 percent to $0.65, and revenue
decreased 4.4 percent to $19.5 billion. The Company expects diluted earnings
per share from continuing operations for fiscal year 2013 to be in the range
of $3.06 to $3.16, an 11 percent to 14 percent increase over fiscal year 2012
diluted earnings per share from continuing operations of $2.76. All results
are presented in accordance with U.S. generally accepted accounting principles
(GAAP).

AmerisourceBergen also announced that it is pursuing the sale of
AndersonBrecon, its contract pharmaceutical packaging business, so that it can
focus on its distribution, specialty, and manufacturer services businesses.
The Company has solicited buyers and is currently reviewing initial bids for
the business. Income from AndersonBrecon has been classified as income from
discontinued operations, and represented $0.04 of the total $2.80 of diluted
earnings per share in fiscal year 2012.

Also today, the Board of Directors increased the dividend paid on common stock
by 62% and declared a regular quarterly cash dividend of $0.21, payable on
December 3, 2012 to shareholders of record on November 19, 2012. In addition,
the Board also approved a new $750 million share repurchase authorization.
Following the completion of a $650 million accelerated share repurchase
program during the September quarter, the Company still has $97 million
remaining on its prior May 2012 authorization, bringing the total amount
authorized for repurchases to $847 million.

Fiscal Fourth Quarter Highlights

  *Diluted earnings per share from continuing operations of $0.65, a 23
    percent increase.
  *Gross profit of $719.5 million, up 18.6 percent.
  *Operating income of $296.3 million, up 24.8 percent.
  *Operating margin of 1.52 percent, up 35 basis points.
  *Cash flow from operations of $545 million.
  *Share repurchases of $648 million.

Fiscal Year 2012 Highlights

  *Diluted earnings per share from continuing operations of $2.76, a 10
    percent increase.
  *Gross profit of $2.7 billion, up 6.7 percent.
  *Operating income of $1.3 billion, up 5.6 percent.
  *Operating margin of 1.58 percent, up 10 basis points.
  *Cash flow from operations of $1.3 billion.
  *Share repurchases of $1.2 billion.

“Solid results across all of our business units and contributions from our
recent acquisitions drove strong performance in the September quarter and in
our full fiscal year 2012,” said Steven H. Collis, AmerisourceBergen President
and Chief Executive Officer. “Outstanding performance in AmerisourceBergen
Drug Corporation (ABDC), particularly in generic pharmaceuticals, helped
overcome a difficult comparison to the prior year and drove operating income
growth and margin expansion. The strength of ABDC, as well as the
opportunities we see ahead for specialty distribution and our manufacturer
services businesses, gave us the confidence to increase our annual dividend by
62% and to complete an accelerated share repurchase of $650 million.

In fiscal 2012, we completed nearly $800 million in acquisitions, and in the
fourth quarter paid down $392 million in debt. Our business continues to
generate excellent cash flow, and going forward we continue to have tremendous
flexibility to reinvest in our business, fund our strategic initiatives, and
return significant value to shareholders. I am very pleased with the
performance our associates delivered this year, and the investments we’ve made
in our future combined with the underlying strength of our business gives me
great confidence in our future.”

Summary of Quarterly Results

  *Revenue: In the fourth quarter of fiscal 2012, revenue was $19.5 billion,
    down 4.4 percent compared to the same quarter in the previous fiscal year,
    reflecting an 8 percent decrease in AmerisourceBergen Drug Corporation
    (ABDC) revenue, offset by a 6 percent increase in AmerisourceBergen
    Specialty Group (ABSG) revenue. Recent acquisitions, including TheraCom
    and World Courier, contributed $335 million of revenue in the quarter.
  *Gross Profit: Gross profit in the fiscal 2012 fourth quarter was $719.5
    million, an 18.6 percent increase over the same period in the previous
    year driven by contributions from our recent acquisitions and strong
    performance in generic pharmaceuticals in ABDC, and included a LIFO credit
    of $10.7 million compared with a $0.1 million credit in the previous
    year’s fourth quarter. Gross profit in the fiscal 2012 fourth quarter also
    included a $14.8 million gain from antitrust litigation settlements,
    compared with a $0.9 million gain in the same period a year ago.
  *Operating Expenses: In the fourth quarter of fiscal 2012, operating
    expenses were $423.3 million, up 14.6 percent over the same period in the
    last fiscal year. The increase in operating expenses was due to the
    operating expenses of our recently acquired companies, and increased
    depreciation and amortization costs, all of which were partially offset by
    a significant improvement in distribution, selling, and administrative
    expenses in our distribution businesses. Operating expenses in the fourth
    quarter of fiscal 2012 and 2011 included employee severance, litigation
    and other costs totaling $29.1 million and $23.6 million respectively.
    Additionally, operating expenses in the fourth quarter of fiscal 2011
    reflected $6.5 million of intangible asset impairments. Operating expenses
    as a percentage of revenue in the fiscal 2012 fourth quarter were 2.18
    percent compared with 1.81 percent in the same period in the previous
    fiscal year.
  *Operating Income: In the fiscal 2012 fourth quarter, operating income
    increased 24.8 percent to $296.3 million due to the increase in gross
    profit. Operating income as a percentage of revenue increased 35 basis
    points to 1.52 percent in the fiscal 2012 fourth quarter compared with the
    previous year’s fourth quarter.
  *Tax Rate: The effective tax rate for the fourth quarter of fiscal 2012 was
    41.6 percent, up from 35.3 percent in the previous fiscal year’s fourth
    quarter, due primarily to a tax valuation allowance related to our
    Canadian distribution business. Going forward, we expect our annualized
    effective tax rate to be approximately 39 percent.
  *Earnings Per Share: Diluted earnings per share from continuing operations
    were up 23 percent to $0.65 in the fourth quarter of fiscal year 2012
    compared to $0.53 in the previous fiscal year’s fourth quarter, reflecting
    the growth in net income and the reduction in diluted average shares
    outstanding.
  *Shares Outstanding: Diluted average shares outstanding for the fourth
    quarter of fiscal year 2012 were 246.5 million, down 9.2 percent from the
    previous fiscal year’s fourth quarter due primarily to share repurchases,
    net of option exercises.

Segment Discussion

The Pharmaceutical Distribution segment includes both AmerisourceBergen Drug
Corporation and AmerisourceBergen Specialty Group. The Other Segment includes
AmerisourceBergen Consulting Services (ABCS) and World Courier. The results of
operations from AndersonBrecon are reported as income from discontinued
operations, and therefore are no longer included in the Other segment.

Pharmaceutical Distribution Segment

In the fourth fiscal quarter of 2012, Pharmaceutical Distribution revenues
were $19.1 billion, a decrease of 6 percent compared to the same quarter in
the prior year. ABDC revenues declined 8 percent, due primarily to a decline
in the volume of sales to our largest customer, and the previously announced
loss of a large retail customer. ABSG revenues increased 6 percent, which was
driven by strong performance in third party logistics and in our vaccine and
physician office distribution business.

Operating income of $307.7 million in the September quarter of 2012 increased
16 percent compared to the same period in the previous year due to strong
contributions from generic conversions in ABDC, growth in certain of our
higher margin specialty distribution businesses and disciplined expense
management. The strong performance of ABDC’s US based operations offset
disappointing performance in its Canadian distribution business.

Other Segment

Revenues in the Other segment were $421.6 million in the fourth quarter of
fiscal 2012, including significant contributions from acquisitions, which were
not included in the same quarter in the previous year. Gross profit and
expenses also increased significantly compared to the prior year due to the
inclusion of operating results from acquisitions completed during fiscal 2012.
Operating income increased significantly to $17.6 million in the third quarter
of 2012, with the majority of the increase provided by acquisitions. TheraCom
and World Courier, our two largest acquisitions in fiscal 2012, each performed
well in the quarter, as did the legacy Consulting Services business. The
fourth quarter in the previous year included a $6.5 million intangible asset
impairment.

Summary of Fiscal Year 2012

In fiscal year 2012, diluted earnings per share were a record $2.76, up 10
percent over the prior fiscal year diluted earnings per share from continuing
operations. Revenue of $79.5 billion decreased 0.6 percent over the last
fiscal year. Operating income rose 5.6 percent to a record $1.3 billion in
fiscal 2012, driven by gross margin expansion and offset in part by an
increase in operating expenses. Operating income margin increased 10 basis
points to 1.58 percent. Diluted average shares outstanding in fiscal 2012 were
256.9 million, down 7.5 percent from the year-ago same period.

Fiscal Year 2013 Expectations

“Looking ahead, the Company expects diluted earnings per share from continuing
operations in fiscal year 2013 to be in the range of $3.06 to $3.16, an 11
percent to 14 percent increase over fiscal 2012,” said Steven H. Collis,
AmerisourceBergen President and Chief Executive Officer. “Key assumptions
supporting that range are: revenue growth in the 6 percent to 9 percent range;
operating income growth in the 3 percent to 5 percent range; an operating
margin decline in the low double-digit basis points range; and free cash flow
in the range of $750 million to $850 million, which includes capital
expenditures in the $180 million range. Subject to market conditions, we
expect to spend at least $200 million to repurchase our common shares in
fiscal year 2013.”

Conference Call

The Company will host a conference call to discuss the results at 11:00 a.m.
Eastern Time on November 1, 2012.


Participating in the conference call will be:
        Steven H. Collis, President & Chief Executive Officer
                Tim G. Guttman, Senior Vice President & Chief Financial
                Officer
                

The dial-in number for the live call will be (612) 332-0107. No access code is
required.

The live call will also be webcast via the Company’s website at
www.amerisourcebergen.com. Users are encouraged to log on to the webcast
approximately 10 minutes in advance of the scheduled start time of the call.

Replays of the call will be made available via telephone and webcast. A replay
of the webcast will be posted on www.amerisourcebergen.com approximately two
hours after the completion of the call and will remain available for thirty
days. The telephone replay will also be available approximately two hours
after the completion of the call and will remain available for seven days. To
access the telephone replay from within the US, dial (800) 475-6701. From
outside the US, dial (320) 365-3844. The access code for the replay is 266794.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With nearly $80 billion in annual revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 13,000 people.
AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information,
go to www.amerisourcebergen.com.

Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section27A of the Securities Act of 1933
and Section21E of the Securities Exchange Act of 1934. These statements are
based on management's current expectations and are subject to uncertainty and
change in circumstances. Among the factors that could cause actual results to
differ materially from those projected, anticipated or implied are the
following: changes in pharmaceutical market growth rates; the loss of one or
more key customer or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or insolvencies;
changes in pharmaceutical manufacturers' pricing and distribution policies or
practices; adverse resolution of any contract or other dispute with customers
or suppliers; federal and state government enforcement initiatives to detect
and prevent suspicious orders of controlled substances and the diversion of
controlled substances; qui tam litigation for alleged violations of fraud and
abuse laws and regulations and/or any other laws and regulations governing the
marketing, sale, purchase, and/or dispensing of pharmaceutical products or
services and any related litigation, including shareholder derivative
lawsuits; changes in federal and state legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we distribute,
including certain anemia products; price inflation in branded pharmaceuticals
and price deflation in generics; greater or less than anticipated benefit from
launches of the generic versions of previously patented pharmaceutical
products; significant breakdown or interruption of our information technology
systems; our inability to continue to implement an enterprise resource
planning (ERP)system to handle business and financial processes and
transactions (including processes and transactions relating to our customers
and suppliers) of AmerisourceBergen Drug Corporation operations as intended
without functional problems, unanticipated delays and/or cost overruns;
success of integration, restructuring or systems initiatives; interest rate
and foreign currency exchange rate fluctuations; risks associated with
international business operations, including non-compliance with the U.S.
Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and
import laws and regulations; economic, business, competitive and/or regulatory
developments outside of the United States; changes and/or potential changes in
Canadian provincial legislation affecting pharmaceutical product pricing or
service fees or regulatory action by provincial authorities in Canada to lower
pharmaceutical product pricing and service fees; the impact of divestitures or
the acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to time;
changes in tax laws or legislative initiatives that could adversely affect our
tax positions and/or our tax liabilities or adverse resolution of challenges
to our tax positions; increased costs of maintaining, or reductions in our
ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting our
business generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those described in
forward-looking statements are set forth (i)in Item1A (Risk Factors) in the
Company's Annual Report on Form 10-K for the fiscal year ended September30,
2011 and elsewhere in that report and (ii)in other reports filed by the
Company pursuant to the Securities Exchange Act of 1934.

                                                                 
AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
                                                                       
                                                                       
                 Three                      Three
                 Months Ended               Months Ended
                 September 30,   % of       September 30,   % of       %
                 2012            Revenue    2011            Revenue    Change
                                                                       
Revenue          $19,452,974     100.00 %   $20,347,188     100.00 %   -4.4  %
                                                                       
Cost of goods    18,733,426                19,740,507                -5.1  %
sold
                                                                       
Gross profit     719,548         3.70   %   606,681         2.98   %   18.6  %
(1)
                                                                       
Operating
expenses:
Distribution,
selling and      353,342         1.82   %   310,582         1.53   %   13.8  %
administrative
Depreciation
and              40,849          0.21   %   28,600          0.14   %   42.8  %
amortization
Employee
severance,       29,100          0.15   %   23,567          0.12   %   23.5  %
litigation and
other (2)
Intangible
asset            -              -      %   6,506          0.03   %
impairments
Total
operating        423,291         2.18   %   369,255         1.81   %   14.6  %
expenses
                                                                       
Operating        296,257         1.52   %   237,426         1.17   %   24.8  %
income
                                                                       
Other income     (910        )   -      %   (2,870      )   -0.01  %
                                                                       
Interest         24,287         0.12   %   19,912         0.10   %   22.0  %
expense, net
                                                                       
Income from
continuing
operations       272,880         1.40   %   220,384         1.08   %   23.8  %
before income
taxes
                                                                       
Income taxes     113,542        0.58   %   77,738         0.38   %   46.1  %
                                                                       
Income from
continuing       159,338         0.82   %   142,646         0.70   %   11.7  %
operations
                                                                       
Income from
discontinued
operations,      4,156                     4,678                     -11.2 %
net of income
taxes
                                                                       
Net income       $163,494       0.84   %   $147,324       0.72   %   11.0  %
                                                                       
                                                                       
Basic earnings
per share:
Continuing       $0.66                      $0.54                      22.2  %
operations
Discontinued     0.02                       0.02
operations
Rounding         (0.01       )              (0.01       )
Total            $0.67                     $0.55                     21.8  %
                                                                       
Diluted
earnings per
share:
Continuing       $0.65                      $0.53                      22.6  %
operations
Discontinued     0.02                       0.02
operations
Rounding         (0.01       )              (0.01       )
Total            $0.66                     $0.54                     22.2  %
                                                                       
Weighted
average common
shares
outstanding:
Basic            242,931                    266,458
Diluted (3)      246,485                    271,385                    -9.2  %
                                                                       

        Includes a $14.8 million gain and a $0.9 million gain from antitrust
 (1)  litigation settlements in the three months ended September 30, 2012
        and 2011, respectively.
        Includes $28.7 million of employee severance and other restructuring
        costs and $0.4 million of acquisition costs related to business
        combinations in the three months ended September 30, 2012. Includes
  (2)   $4.4 million of employee severance costs, a $16.0 million charge
        related to a Qui Tam litigation settlement and $3.2 million of
        acquisition costs related to business combinations in the three months
        ended September 30, 2011.
  (3)   Includes the dilutive effect of stock options, restricted stock, and
        restricted stock units.


AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY
(In thousands, except per share data)
(unaudited)
                                                                  
                                                                        
                  Fiscal                     Fiscal
                  Year Ended                 Year Ended
                  September 30,   % of       September 30,   % of       %
                  2012            Revenue    2011            Revenue    Change
                                                                        
Revenue           $79,489,596     100.00 %   $80,003,844     100.00 %   -0.6 %
                                                                        
Cost of goods     76,820,498                77,502,249                -0.9 %
sold
                                                                        
Gross profit      2,669,098       3.36   %   2,501,595       3.13   %   6.7  %
(1)
                                                                        
Operating
expenses:
Distribution,
selling and       1,229,495       1.55   %   1,179,234       1.47   %   4.3  %
administrative
Depreciation
and               141,054         0.18   %   105,482         0.13   %   33.7 %
amortization
Employee
severance,        45,821          0.06   %   23,567          0.03   %   94.4 %
litigation and
other (2)
Intangible
asset             -              -      %   6,506          0.01   %
impairments
Total operating   1,416,370       1.78   %   1,314,789       1.64   %   7.7  %
expenses
                                                                        
Operating         1,252,728       1.58   %   1,186,806       1.48   %   5.6  %
income
                                                                        
Other income      (5,827      )   -0.01  %   (4,617      )   -0.01  %
                                                                        
Interest          95,424         0.12   %   76,689         0.10   %   24.4 %
expense, net
                                                                        
Income from
continuing
operations        1,163,131       1.46   %   1,114,734       1.39   %   4.3  %
before income
taxes
                                                                        
Income taxes      454,945        0.57   %   418,802        0.52   %   8.6  %
                                                                        
Income from
continuing        708,186         0.89   %   695,932         0.87   %   1.8  %
operations
                                                                        
Income from
discontinued      10,800                    10,692                    1.0  %
operations, net
of income taxes
                                                                        
Net income        $718,986       0.90   %   $706,624       0.88   %   1.7  %
                                                                        
                                                                        
Basic earnings
per share:
Continuing        $2.80                      $2.55                      9.8  %
operations
Discontinued      0.04                      0.04        
operations
Total             $2.84                     $2.59                     9.7  %
                                                                        
Diluted
earnings per
share:
Continuing        $2.76                      $2.51                      10.0 %
operations
Discontinued      0.04                       0.04
operations
Rounding          -                         (0.01       )
Total             $2.80                     $2.54                     10.2 %
                                                                        
Weighted
average common
shares
outstanding:
Basic             252,906                    272,471
Diluted (3)       256,903                    277,717                    -7.5 %
                                                                        

        Includes a $14.8 million gain and a $2.1 million gain from antitrust
 (1)  litigation settlements in the fiscal years ended September 30, 2012
        and 2011, respectively.
        Includes $34.7 million of employee severance and other restructuring
        costs and $11.1 million of acquisition costs related to business
        combinations in the fiscal year ended September 30, 2012. Includes
  (2)   $4.4 million of employee severance costs, a $16.0 million charge
        related to a Qui Tam litigation settlement and $3.2 million of
        acquisition costs related to business combinations in the fiscal year
        ended September 30, 2011.
  (3)   Includes the dilutive effect of stock options, restricted stock, and
        restricted stock units.
        

                                                          
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
                                                             
                                                             
ASSETS
                                             September 30,   September 30,
                                             2012            2011
Current assets:
Cash and cash equivalents                    $1,066,608      $1,825,990
Accounts receivable, net                     3,938,597       3,793,850
Merchandise inventories                      5,689,147       5,443,101
Prepaid expenses and other                   73,811          86,663
Assets held for sale                         218,988         225,437
Total current assets                         10,987,151      11,375,041
                                                             
Property and equipment, net                  780,013         672,862
Other long-term assets                       3,676,962       2,934,768
                                                             
Total assets                                 $15,444,126     $14,982,671
                                                             
                                                             
LIABILITIES AND STOCKHOLDERS' EQUITY
                                                             
Current liabilities:
Accounts payable                             $9,630,110      $9,191,428
Current portion of long-term debt            -               392,089
Other current liabilities                    1,535,534       1,249,209
Liabilities held for sale                    48,838          42,538
Total current liabilities                    11,214,482      10,875,264
                                                             
Long-term debt, less current portion         1,446,770       972,863
                                                             
Other long-term liabilities                  326,162         267,686
                                                             
Stockholders' equity                         2,456,712       2,866,858
                                                             
Total liabilities and stockholders' equity   $15,444,126     $14,982,671
                                                             

                                                              
AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
                                                                 
                                                 Fiscal          Fiscal
                                                 Year Ended      Year Ended
                                                 September 30,   September 30,
                                                 2012            2011
                                                                 
Operating Activities:
Net income                                       $718,986        $706,624
Income from discontinued operations              (10,800     )   (10,692     )
Income from continuing operations                708,186         695,932
Adjustments to reconcile income from
continuing operations to net cash provided by    261,030         377,310
operating activities
Changes in operating assets and liabilities      301,326        88,370      
Net cash provided by operating activities -      1,270,542       1,161,612
continuing operations
Net cash provided by operating activities -      34,907         6,336       
discontinued operations
Net cash provided by operating activities        1,305,449      1,167,948   
                                                                 
Investing Activities:
Capital expenditures                             (164,041    )   (157,709    )
Cost of acquired companies, net of cash          (775,670    )   (45,380     )
acquired
Other                                            23             874         
Net cash used in investing activities -          (939,688    )   (202,215    )
continuing operations
Net cash used in investing activities -          (8,261      )   (10,203     )
discontinued operations
Net cash used in investing activities            (947,949    )   (212,418    )
                                                                 
Financing Activities:
Net borrowings                                   73,558          22,435
Purchases of common stock                        (1,162,246  )   (840,577    )
Exercises of stock options                       115,224         155,531
Cash dividends on common stock                   (132,760    )   (117,624    )
Debt issuance costs and other                    (10,658     )   (7,439      )
Net cash used in financing activities -          (1,116,882  )   (787,674    )
continuing operations
Net cash used in financing activities -          -              (48         )
discontinued operations
Net cash used in financing activities            (1,116,882  )   (787,722    )
                                                                 
(Decrease) increase in cash and cash             (759,382    )   167,808
equivalents
                                                                 
Cash and cash equivalents at beginning of year   1,825,990      1,658,182   
                                                                 
Cash and cash equivalents at end of year         $1,066,608     $1,825,990  
                                                                 


AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
                                                                  
                                                                      
                                      Three Months Ended September 30,
Revenue                               2012           2011           % Change
                                                                      
Pharmaceutical Distribution           $19,085,352     $20,286,608     -6    %
Other (1)                             421,566         74,743          464   %
Intersegment eliminations             (53,944     )   (14,163     )   281   %
                                                                      
Revenue                               $19,452,974    $20,347,188    -4    %
                                                                      
                                                                      
                                                                      
                                                                      
                                      Three Months Ended September 30,
Operating Income                      2012           2011           % Change
                                                                      
Pharmaceutical Distribution           $307,744        $264,209        16    %
Other (1)                             17,613          (3,216      )   648   %
Employee severance, litigation and    (29,100     )   (23,567     )   23    %
other
                                                                      
Operating income                      $296,257       $237,426       25    %
                                                                      
                                                                      
                                                                      
                                                                      
Percentages of revenue:
                                                                      
Pharmaceutical Distribution
Gross profit                          3.23        %   2.88        %
Operating expenses                    1.62        %   1.58        %
Operating income                      1.61        %   1.30        %
                                                                      
Other (1)
Gross profit                          24.30       %   29.61       %
Operating expenses                    20.12       %   33.91       %
Operating income                      4.18        %   -4.30       %
                                                                      
AmerisourceBergen Corporation
Gross profit                          3.70        %   2.98        %
Operating expenses                    2.18        %   1.81        %
Operating income                      1.52        %   1.17        %
                                                                      

(1) The Other reportable segment in fiscal 2012 is comprised of the
AmerisourceBergen Consulting Services ("ABCS") operating segment and the World
Courier Group, Inc. operating segment. The Other reportable segment in fiscal
2011 is comprised solely of the ABCS operating segment.


AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
(unaudited)
                                                                  
                                                                      
                                      Fiscal Year Ended September 30,
Revenue                               2012           2011           % Change
                                                                      
Pharmaceutical Distribution           $78,349,334     $79,753,118     -2    %
Other (1)                             1,324,744       302,012         339   %
Intersegment eliminations             (184,482    )   (51,286     )   260   %
                                                                      
Revenue                               $79,489,596    $80,003,844    -1    %
                                                                      
                                                                      
                                                                      
                                                                      
                                      Fiscal Year Ended September 30,
Operating Income                      2012           2011           % Change
                                                                      
Pharmaceutical Distribution           $1,226,430      $1,181,959      4     %
Other (1)                             72,119          28,414          154   %
Employee severance, litigation and    (45,821     )   (23,567     )   94    %
other
                                                                      
Operating income                      $1,252,728     $1,186,806     6     %
                                                                      
                                                                      
                                                                      
                                                                      
Percentages of revenue:
                                                                      
Pharmaceutical Distribution
Gross profit                          3.06        %   3.01        %
Operating expenses                    1.49        %   1.53        %
Operating income                      1.57        %   1.48        %
                                                                      
Other (1)
Gross profit                          20.49       %   33.45       %
Operating expenses                    15.04       %   24.04       %
Operating income                      5.44        %   9.41        %
                                                                      
AmerisourceBergen Corporation
Gross profit                          3.36        %   3.13        %
Operating expenses                    1.78        %   1.64        %
Operating income                      1.58        %   1.48        %
                                                                      

(1) The Other reportable segment in fiscal 2012 is comprised of the
AmerisourceBergen Consulting Services ("ABCS") operating segment and the World
Courier Group, Inc. operating segment. The Other reportable segment in fiscal
2011 is comprised solely of the ABCS operating segment.


Contact:

AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
bbrungess@amerisourcebergen.com
 
Press spacebar to pause and continue. Press esc to stop.